CAI
Caris Life Sciences, Inc.
31.50$
+2.7%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 31.6% | 34.3% | 49.6% | 53.3% | 51.4% | 50.6% | 51.9% | 37.4% | 69.0% | 70.8% | 56.6% | 33.6% | |
| 68.4% | 65.7% | 50.4% | 46.7% | 48.6% | 49.4% | 48.1% | 62.6% | 31.0% | 29.2% | 43.4% | 66.4% | |
| – | – | – | – | – | – | – | – | 39.2% | 38.2% | 27.6% | 5.6% | |
| 9.1% | – | 11.1% | 12.1% | 12.3% | 11.6% | 12.7% | 9.3% | 60.4% | 49.6% | 42.1% | 27.7% | |
| 20.7% | 23.1% | 23.2% | 24.3% | 18.3% | 15.0% | 16.9% | 15.3% | 153.1% | 133.6% | 105.7% | 60.8% | |
| 47.7% | 42.6% | 27.3% | 22.4% | 30.3% | 34.4% | 31.3% | 47.3% | -122.2% | -104.4% | -62.4% | 5.6% | |
| 17.0% | 15.5% | 14.4% | 14.5% | 15.2% | 18.1% | 19.0% | 20.9% | 10.3% | 10.3% | 12.1% | 7.0% | |
| 33.7% | 29.7% | 12.5% | 3.4% | 16.4% | 18.9% | 13.3% | 10.0% | -124.1% | -111.5% | -68.4% | -8.4% | |
| 3.3% | 3.2% | 1.7% | 1.3% | -4.3% | 0.7% | 1.0% | 0.6% | – | – | – | 57.9% | |
| 30.1% | 26.5% | 10.7% | 2.0% | 20.7% | 18.2% | 7.4% | 9.4% | -124.1% | -111.5% | -68.4% | -66.2% | |
| 82.6% | 79.8% | 72.6% | 54.1% | 64.2% | 65.6% | 59.6% | 86.5% | -95.1% | -85.2% | -44.4% | 1.4% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.